DC
NRXP icon

Davenport & Co’s NRX Pharmaceuticals NRXP Stock Holding History

Davenport & Co’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,000
Closed -$7K – 1023
2022
Q3 		$7K Hold
1,000
– – ﹤0.01% 989
2022
Q2 		$6K Hold
1,000
– – ﹤0.01% 987
2022
Q1 		$25K Hold
1,000
– – ﹤0.01% 1052
2021
Q4 		$48K Buy
+1,000
New +$72.2K ﹤0.01% 1063

Other funds holding NRXP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Davenport & Co's NRXP Position: Q4 2022 in Review

Davenport & Co sold out of NRX Pharmaceuticals (NRXP) in Q4 2022, closing a stake of 1,000 shares — an estimated $7K sold.

Davenport & Co first reported a position in NRXP in Q4 2021 and held it in 4 quarters. The position peaked at $48K in Q4 2021. 33 funds tracked by Wall St. Rank hold NRXP as of Q4 2022.

  • Davenport & Co reported no remaining NRX Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Davenport & Co sold 1,000 NRX Pharmaceuticals shares in Q4 2022, an estimated $7K.
  • Davenport & Co first reported a position in NRX Pharmaceuticals in Q4 2021 and held it in 4 quarters.
  • Davenport & Co's NRX Pharmaceuticals position peaked at $48K in Q4 2021.
  • 33 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q4 2022.

Based on Davenport & Co's 13F filing for Q4 2022, filed 20 Jan 2023.